These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Intrarenal conversion of big endothelin-1 to endothelin-1 in the rat. Fujita K, Matsumura Y, Kita S, Hisaki K, Takaoka M, Morimoto S. Life Sci; 1994; 55(16):1285-91. PubMed ID: 7934630 [Abstract] [Full Text] [Related]
4. Phosphoramidon inhibits the conversion of big ET-1 into ET-1 in the pithed rat and in isolated perfused rat kidneys. Verbeuren TJ, Mennecier P, Merceron D, Simonet S, de Nanteuil G, Vincent M, Laubie M. J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S81-4. PubMed ID: 7510006 [Abstract] [Full Text] [Related]
6. Evidence for metalloprotease involvement in the in vivo effects of big endothelin 1. Pollock DM, Opgenorth TJ. Am J Physiol; 1991 Jul; 261(1 Pt 2):R257-63. PubMed ID: 1650147 [Abstract] [Full Text] [Related]
11. Conversion of big endothelin-1 and characterization of its contractile effects on isolated human placental arteries. Hanson GC, Wide-Swenson D, Andersson KE, Lindberg BF. Gynecol Obstet Invest; 1998 Jul; 45(1):1-6. PubMed ID: 9473154 [Abstract] [Full Text] [Related]
12. Conversion of big ET-1 in the rat lung: role of phosphoramidon-sensitive endothelin-1-converting enzyme. Hisaki K, Matsumura Y, Maekawa H, Fujita K, Takaoka M, Morimoto S. Am J Physiol; 1994 Feb; 266(2 Pt 2):H422-8. PubMed ID: 8141343 [Abstract] [Full Text] [Related]
13. Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1. Matsumura Y, Hisaki K, Takaoka M, Morimoto S. Eur J Pharmacol; 1990 Aug 21; 185(1):103-6. PubMed ID: 2226629 [Abstract] [Full Text] [Related]
14. Presence of a phosphoramidon-sensitive endothelin-converting enzyme which converts big-endothelin-1, but not big-endothelin-3, in the rat vas deferens. Télémaque S, D'Orléans-Juste P. Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct 21; 344(4):505-7. PubMed ID: 1766477 [Abstract] [Full Text] [Related]
15. Rhamnose moiety of phosphoramidon is not required for in vivo inhibition of endothelin converting enzyme. Pollock DM, Shiosaki K, Sullivan GM, Opgenorth TJ. Biochem Biophys Res Commun; 1992 Jul 31; 186(2):1146-50. PubMed ID: 1497648 [Abstract] [Full Text] [Related]
16. Human big endothelin releases prostacyclin in vivo and in vitro through a phosphoramidon-sensitive conversion to endothelin-1. D'Orléans-Juste P, Lidbury PS, Telemaque S, Warner TD, Vane JR. J Cardiovasc Pharmacol; 1991 Jul 31; 17 Suppl 7():S251-5. PubMed ID: 1725347 [Abstract] [Full Text] [Related]
17. Conversion of big endothelin-1 to endothelin-1 by phosphoramidon-sensitive metalloproteinase derived from aortic endothelial cells. Matsumura Y, Ikegawa R, Hisaki K, Tsukahara Y, Takaoka M, Morimoto S. J Cardiovasc Pharmacol; 1991 Jul 31; 17 Suppl 7():S65-7. PubMed ID: 1725435 [Abstract] [Full Text] [Related]
18. Human brain contains a metalloprotease that converts big endothelin-1 to endothelin-1 and is inhibited by phosphoramidon and EDTA. Warner TD, Schmidt HH, Kuk J, Mitchell JA, Murad F. Br J Pharmacol; 1992 Jul 31; 106(3):505-6. PubMed ID: 1504735 [Abstract] [Full Text] [Related]
19. Pharmacologic evidence for the specificity of the phosphoramidon-sensitive endothelin-converting enzyme for big endothelin-1. Télémaque S, Gratton JP, Claing A, D'Orléans-Juste P. J Cardiovasc Pharmacol; 1993 Jul 31; 22 Suppl 8():S85-9. PubMed ID: 7510007 [Abstract] [Full Text] [Related]